Medivir AB (MVIR B) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Cantargia AB

Oncopeptides AB

Medivir AB

Xbrane Biopharma AB

Orexo AB

Diamyd Medical AB

Cereno Scientific AB

SynAct Pharma AB

FluoGuide A/S

Initiator Pharma A/S

Kancera AB

Why is Medivir AB ?

Poor long term growth as Net Sales has grown by an annual rate of -9.37% over the last 5 years

The company has declared Negative results for the last 3 consecutive quarters

INTEREST(9M) At SEK 1.9 MM has Grown at inf%
DEBT-EQUITY RATIO (HY) Highest at 0 %
CASH AND EQV(HY) Lowest at SEK 142.7 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 75.54%, its profits have risen by 7.6%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Medivir AB for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Medivir AB

75.54%

-0.14

157.06%

OMX Stockholm 30

10.97%

0.59

18.59%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-9.37%

EBIT Growth (5y)

-8.36%

EBIT to Interest (avg)

-78.25

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.34

Sales to Capital Employed (avg)

0.04

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.77

EV to EBIT

-0.24

EV to EBITDA

-0.24

EV to Capital Employed

0.56

EV to Sales

5.84

PEG Ratio

Dividend Yield

ROCE (Latest)

-239.86%

ROE (Latest)

-122.99%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company

NET SALES(HY)

Higher at SEK 6.4 MM

NET PROFIT(HY)

Higher at SEK -57.8 MM

RAW MATERIAL COST(Y)

Fallen by -71.53% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 2.15 times

OPERATING PROFIT(Q)

Highest at SEK -11.9 MM

-15What is not working for the Company

INTEREST(9M)

At SEK 1.9 MM has Grown at inf%

DEBT-EQUITY RATIO (HY)

Highest at 0 %

CASH AND EQV(HY)

Lowest at SEK 142.7 MM

PRE-TAX PROFIT(Q)

Lowest at SEK -43.2 MM

NET PROFIT(Q)

Lowest at SEK -43.2 MM

Here's what is working for Medivir AB

Net Sales

At SEK 6.4 MM has Grown at 236.84%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (SEK MM)

Net Sales

Higher at SEK 6.4 MM

than preceding 12 month period ended Dec 2025

MOJO Watch

In the half year the company has already crossed sales of the previous twelve months

Net Sales (SEK MM)

Operating Profit

Highest at SEK -11.9 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (SEK MM)

Debtors Turnover Ratio

Highest at 2.15 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -71.53% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at SEK 30.5 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (SEK MM)

Depreciation

At SEK 30.5 MM has Grown at 4,257.14%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (SEK MM)

Here's what is not working for Medivir AB

Interest

At SEK 1.9 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (SEK MM)

Pre-Tax Profit

At SEK -43.2 MM has Fallen at -61.8%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (SEK MM)

Net Profit

At SEK -43.2 MM has Fallen at -61.8%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (SEK MM)

Debt-Equity Ratio

Highest at 0 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Pre-Tax Profit

Lowest at SEK -43.2 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (SEK MM)

Net Profit

Lowest at SEK -43.2 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is negative

Net Profit (SEK MM)

Cash and Eqv

Lowest at SEK 142.7 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents